Veru-111, cytoskeleton disruptor, demonstrates efficacy in preclinical models of human triple negative breast cancer

-- preclinical data presented at the 2020 san antonio breast cancer symposium-- -- veru-111 has anticancer activity in both paclitaxel sensitive and paclitaxel resistant triple negative breast cancer tumors-- --veru plans to meet with fda and advance veru-111 into a phase 2b clinical trial in women with paclitaxel resistant triple negative breast cancer in 2021--
VERU Ratings Summary
VERU Quant Ranking